ID: ALA4461590

Max Phase: Preclinical

Molecular Formula: C16H13N3O4S

Molecular Weight: 343.36

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COC(=O)c1ccc(Oc2ccnc3sc(C(N)=O)c(N)c23)cc1

Standard InChI:  InChI=1S/C16H13N3O4S/c1-22-16(21)8-2-4-9(5-3-8)23-10-6-7-19-15-11(10)12(17)13(24-15)14(18)20/h2-7H,17H2,1H3,(H2,18,20)

Standard InChI Key:  XCHOABOLVNNQRU-UHFFFAOYSA-N

Associated Targets(non-human)

Alkaline phosphatase tissue-nonspecific 94 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 343.36Molecular Weight (Monoisotopic): 343.0627AlogP: 2.56#Rotatable Bonds: 4
Polar Surface Area: 117.53Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 0.83CX LogP: 2.31CX LogD: 2.31
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.70Np Likeness Score: -1.06

References

1. Saito K, Shinozuka T, Nakao A, Kiho T, Kunikata T, Shiiki T, Nagai Y, Naito S..  (2019)  Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.,  29  (14): [PMID:31101474] [10.1016/j.bmcl.2019.05.014]

Source